Agenus Inc. published a medical research presentation on how systemic inflammation and tumor-microenvironment immune features are associated with outcomes in patients with immunologically cold, treatment-refractory tumors treated with botensilimab, including in combination with balstilimab. The document summarizes efficacy and overall survival analyses, compares outcomes by prior immune checkpoint inhibitor exposure and early immune-mediated adverse events, and reports exploratory biomarker findings from the C-800-01 clinical trial. The full document can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on February 19, 2026, and is solely responsible for the information contained therein.